Research and Development

FDA Recommends Trial Designs for Unresponsive Non-Muscle Invasive Bladder Cancer

The FDA published recommendations for clinical trial designs for patients with bladder cancer, with separate considerations for patients with and without active disease. The agency’s draft guidance focuses on developing drugs and biologics for non-muscle invasive disease that has not responded to treatment with bacillus Calmette-Guerin immunotherapy. Read More